Fatty liver disease

disease

On this page

Also known as fatty liver

Summary

Fatty liver disease (MONDO:0004790) is a disease with 5 cohort genes (16 GWAS associations across 8 studies) and 203 clinical trials. Top therapeutic interventions include vitamin e, choline, and liraglutide.

At a glance

Cohort genes: 5
GWAS associations: 16
ClinVar variants: 6
Clinical trials: 203

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	fatty liver disease
Mondo ID	MONDO:0004790
MeSH	D005234
DOID	DOID:9452
SNOMED CT	197321007, 371330000
UMLS	C2711227
MedGen	398225
Is cancer (heuristic)	no

Also known as: fatty liver

Data availability: 6 ClinVar variants · 16 GWAS associations (8 studies).

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › fatty liver disease

Subtypes (4): visceral steatosis, congenital, metabolic dysfunction-associated steatotic liver disease, alcoholic fatty liver disease, metabolic dysfunction and alcohol associated liver disease

Genetics & variants

GWAS landscape

16 GWAS associations across 8 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs738409	2e-49	PNPLA3	?	1.39
rs12483959	1e-30	PNPLA3	A	0.36
rs150641967	2e-13	HAPLN4	?	1.33
rs2294433	4e-08	PNPLA3	A	1.43
rs115270700	3e-07	C1QTNF12 - UBE2J2	C	1.51
rs202913	4e-07	LINC01643 - ACO2P1	A	0.7
rs6718356	3e-06	LINC01121	A	1.65
rs2294919	4e-06	PNPLA3	T	0.73
rs77420554	4e-06	RNU6-54P - MTCL1P1	T	0.64
rs17030882	5e-06	CAMTA1	T	1.49
rs708844	6e-06	LINC02463	A	0.58
rs2332961	6e-06	LINC01924	T	1.35
rs1321257	7e-06	GALNT2	A	1.37
rs4879960	7e-06	CLTA	C	0.53
rs2431741	8e-06	PWWP2A	T	1.35

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90727170	Kim HI	2026	4,256	39,770	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90726555	Jo J	2025	3,524	57,445	Association of Multiple-trait Polygenic Risk Score with Obesity and Cardiometabolic Diseases in Korean Population.
GCST90080288	Backman JD	2021	2,432	385,498	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084274	Backman JD	2021	2,432	385,498	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90132296	Lee HW	2022	1,018	1,803	Impact of Evolutionary Changes in Nonalcoholic Fatty Liver Disease on Lung Function Decline.
GCST90132297	Lee HW	2022	951	1,771	Impact of Evolutionary Changes in Nonalcoholic Fatty Liver Disease on Lung Function Decline.
GCST90837524	Koyama S	2025	0	0	Genetics and context for precision health in Greater Boston.
GCST90104150	Choe EK	2022	0	0	Leveraging deep phenotyping from health check-up cohort with 10,000 Korean individuals for phenome-wide association study of 136 traits.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	1
Tier 3: regulatory	0
Tier 4: intronic/intergenic	13

MAF distribution

Bucket	Variants
common (>=0.05)	15
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	12
missense_variant	1
non_coding_transcript_exon_variant	1
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs738409	22	43928847	C>A,G,T	0.05	missense_variant	PNPLA3	2e-49	Tier 1: coding
rs12483959	22	43930116	G>A,C,T	0.42	intron_variant	PNPLA3	1e-30	Tier 4: intronic/intergenic
rs150641967	19	19259532	TGACA>T,TGACAGACA	0.05	intron_variant	HAPLN4	2e-13	Tier 4: intronic/intergenic
rs2294433	22	43933395	G>A,C,T	0.05	intron_variant	PNPLA3	4e-08	Tier 4: intronic/intergenic
rs115270700	1	1250144	T>C,G	0.05	non_coding_transcript_exon_variant	C1QTNF12 - UBE2J2	3e-07	Tier 4: intronic/intergenic
rs202913	22	34287761	G>A,C	0.05	intron_variant	LINC01643 - ACO2P1	4e-07	Tier 4: intronic/intergenic
rs6718356	2	45198516	G>A	0.05	intron_variant	LINC01121	3e-06	Tier 4: intronic/intergenic
rs2294919	22	43946445	C>G,T	0.05	3_prime_UTR_variant	PNPLA3	4e-06	Tier 2: splice/UTR
rs77420554	13	70847558	C>A,T	0.05	intron_variant	RNU6-54P - MTCL1P1	4e-06	Tier 4: intronic/intergenic
rs17030882	1	7445157	C>T	0.05	intron_variant	CAMTA1	5e-06	Tier 4: intronic/intergenic
rs708844	12	115870919	T>A	0.05	intron_variant	LINC02463	6e-06	Tier 4: intronic/intergenic
rs2332961	18	64361382	C>T	0.05	intron_variant	LINC01924	6e-06	Tier 4: intronic/intergenic
rs1321257	1	230169566	G>A	0.05	intron_variant	GALNT2	7e-06	Tier 4: intronic/intergenic
rs4879960	9	36203721	T>C	0.05	intron_variant	CLTA	7e-06	Tier 4: intronic/intergenic
rs2431741	5	160110796	T>A,C,G	0.05	intron_variant	PWWP2A	8e-06	Tier 4: intronic/intergenic

ClinVar germline variants

6 retrieved; paginated sample, class counts are floors:

2 pathogenic/likely pathogenic, 1 conflicting classifications of pathogenicity, 1 conflicting classifications of pathogenicity; risk factor, 1 benign, 1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
996695	NM_003680.4(YARS1):c.806T>C (p.Phe269Ser)	LOC126805688	Pathogenic/Likely pathogenic	no assertion criteria provided
523434	NM_019023.5(PRMT7):c.1713C>A (p.Cys571Ter)	PRMT7	Pathogenic	criteria provided, multiple submitters, no conflicts
523435	NM_019023.5(PRMT7):c.322G>T (p.Glu108Ter)	PRMT7	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
214916	NM_130837.3(OPA1):c.113_130del (p.Arg38_Ser43del)	OPA1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
341932	NM_025225.3(PNPLA3):c.444C>G (p.Ile148Met)	PNPLA3	Conflicting classifications of pathogenicity; risk factor	criteria provided, conflicting classifications
370045	NC_012920.1(MT-TL1):m.3275C>T	MT-TL1	Benign	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 15 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MED12	Orphanet:1415	Hardikar syndrome
MED12	Orphanet:293707	Blepharophimosis-intellectual disability syndrome, MKB type
MED12	Orphanet:776	Lujan-Fryns syndrome
MED12	Orphanet:777	X-linked non-syndromic intellectual disability
MED12	Orphanet:93932	FG syndrome type 1
PRMT7	Orphanet:464288	Short stature-brachydactyly-obesity-global developmental delay syndrome
MT-TL1	Orphanet:255210	Mitochondrial DNA-associated Leigh syndrome
MT-TL1	Orphanet:324525	Hypertrophic cardiomyopathy with kidney anomalies due to mitochondrial DNA mutation
MT-TL1	Orphanet:480	Kearns-Sayre syndrome
MT-TL1	Orphanet:550	MELAS
MT-TL1	Orphanet:551	MERRF
MT-TL1	Orphanet:663	Mitochondrial DNA-related progressive external ophthalmoplegia
OPA1	Orphanet:1215	Autosomal dominant optic atrophy plus syndrome
OPA1	Orphanet:1239	Behr syndrome
OPA1	Orphanet:98673	Autosomal dominant optic atrophy, classic form

Cohort genes → proteins

5 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MED12	HGNC:11957	ENSG00000184634	Q93074	Mediator of RNA polymerase II transcription subunit 12	clinvar
PNPLA3	HGNC:18590	ENSG00000100344	Q9NST1	1-acylglycerol-3-phosphate O-acyltransferase PNPLA3	clinvar
PRMT7	HGNC:25557	ENSG00000132600	Q9NVM4	Protein arginine N-methyltransferase 7	clinvar
MT-TL1	HGNC:7490	ENSG00000209082		mitochondrially encoded tRNA-Leu (UUA/G) 1	clinvar
OPA1	HGNC:8140	ENSG00000198836	O60313	Dynamin-like GTPase OPA1, mitochondrial	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MED12	Mediator of RNA polymerase II transcription subunit 12	Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes.
PNPLA3	1-acylglycerol-3-phosphate O-acyltransferase PNPLA3	Specifically catalyzes coenzyme A (CoA)-dependent acylation of 1-acyl-sn-glycerol 3-phosphate (2-lysophosphatidic acid/LPA) to generate phosphatidic acid (PA), an important metabolic intermediate and precursor for both triglycerides and gl…
PRMT7	Protein arginine N-methyltransferase 7	Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA.
OPA1	Dynamin-like GTPase OPA1, mitochondrial	Dynamin-related GTPase that is essential for normal mitochondrial morphology by mediating fusion of the mitochondrial inner membranes, regulating cristae morphology and maintaining respiratory chain function.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.4

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	2	4.8×	0.117
Other/Unknown	3	1.1×	0.608

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MED12	Other/Unknown	no		Mediator_Med12, Mediator_Med12_catenin-bd, Mediator_Med12_LCEWAV
PNPLA3	Other/Unknown	no		PNPLA_dom, Acyl_Trfase/lysoPLipase, PLPL
PRMT7	Enzyme (other)	yes	2.1.1.321	MeTrfase_PRMT7, Arg_MeTrfase, SAM-dependent_MTases_sf
MT-TL1	Other/Unknown	no
OPA1	Enzyme (other)	yes	3.6.5.5	Dynamin_GTPase, Dynamin, P-loop_NTPase

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
left ovary	1
right adrenal gland	1
right adrenal gland cortex	1
buccal mucosa cell	1
pigmented layer of retina	1
right lobe of liver	1
cerebellar cortex	1
cerebellar hemisphere	1
right hemisphere of cerebellum	1
caudate nucleus	1
frontal cortex	1
right frontal lobe	1
adrenal tissue	1
calcaneal tendon	1
endothelial cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MED12	281	ubiquitous	marker	right adrenal gland cortex, right adrenal gland, left ovary
PNPLA3	178	ubiquitous	marker	pigmented layer of retina, buccal mucosa cell, right lobe of liver
PRMT7	186	ubiquitous	marker	right hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex
MT-TL1	118	ubiquitous	marker	frontal cortex, right frontal lobe, caudate nucleus
OPA1	288	ubiquitous	marker	adrenal tissue, calcaneal tendon, endothelial cell

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MED12	3,322
OPA1	2,630
PRMT7	2,036
PNPLA3	1,441
MT-TL1	0

Structural data

PDB: 2 · AlphaFold-only: 2 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
OPA1	O60313	11
MED12	Q93074	3

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
PRMT7	Q9NVM4	93.19
PNPLA3	Q9NST1	71.70

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 26. Enrichment computed across 5 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Regulation of Apoptosis	1	475.8×	0.032	OPA1
Acyl chain remodeling of DAG and TAG	1	407.9×	0.032	PNPLA3
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	1	53.9×	0.072	MED12
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	1	49.2×	0.072	MED12
Respiratory Syncytial Virus Infection Pathway	1	49.2×	0.072	MED12
RSV-host interactions	1	39.1×	0.072	MED12
Adipogenesis	1	39.1×	0.072	MED12
Epigenetic regulation by WDR5-containing histone modifying complexes	1	38.6×	0.072	MED12
RMTs methylate histone arginines	1	36.6×	0.072	PRMT7
Regulation of lipid metabolism by PPARalpha	1	35.2×	0.072	MED12
Transcriptional regulation of white adipocyte differentiation	1	32.4×	0.072	MED12
Mitochondrial protein degradation	1	28.6×	0.075	OPA1
PPARA activates gene expression	1	23.6×	0.083	MED12
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis	1	20.7×	0.083	MED12
Chromatin organization	1	20.4×	0.083	PRMT7
Chromatin modifying enzymes	1	18.1×	0.084	PRMT7
Epigenetic regulation of gene expression	1	17.8×	0.084	MED12
Metabolism of lipids	1	7.9×	0.169	MED12
Viral Infection Pathways	1	7.7×	0.169	MED12
Infectious disease	1	6.2×	0.197	MED12
RNA Polymerase II Transcription	1	5.6×	0.206	MED12
Gene expression (Transcription)	1	4.5×	0.244	MED12
Generic Transcription Pathway	1	3.8×	0.270	MED12
Developmental Biology	1	3.6×	0.270	MED12
Disease	1	3.3×	0.283	MED12
Metabolism	1	2.9×	0.302	MED12

GO biological processes by enrichment

GO term	Cohort genes	Fold	FDR	Sample cohort genes
triglyceride acyl-chain remodeling	1	4213.0×	0.004	PNPLA3
mitochondrial inner membrane fusion	1	4213.0×	0.004	OPA1
neural tube closure	2	93.6×	0.004	MED12, OPA1
cellular response to 3,3’,5-triiodo-L-thyronine	1	2106.5×	0.006	PNPLA3
axis elongation involved in somitogenesis	1	1404.3×	0.006	MED12
membrane tubulation	1	1404.3×	0.006	OPA1
peptidyl-arginine methylation	1	1053.2×	0.006	PRMT7
acylglycerol acyl-chain remodeling	1	1053.2×	0.006	PNPLA3
response to sucrose	1	842.6×	0.007	PNPLA3
glycerophospholipid metabolic process	1	702.2×	0.008	PNPLA3
positive regulation of T-helper 17 cell lineage commitment	1	526.6×	0.009	OPA1
embryonic neurocranium morphogenesis	1	468.1×	0.009	MED12
peroxisome fission	1	383.0×	0.010	OPA1
axonal transport of mitochondrion	1	351.1×	0.010	OPA1
GTP metabolic process	1	280.9×	0.010	OPA1
mitochondrial fission	1	263.3×	0.010	OPA1
Schwann cell development	1	263.3×	0.010	MED12
cristae formation	1	263.3×	0.010	OPA1
genomic imprinting	1	247.8×	0.010	PRMT7
lipid droplet organization	1	234.1×	0.010	PNPLA3
inner mitochondrial membrane organization	1	210.7×	0.010	OPA1
mitochondrial fusion	1	210.7×	0.010	OPA1
white fat cell differentiation	1	210.7×	0.010	PNPLA3
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	1	210.7×	0.010	OPA1
triglyceride catabolic process	1	200.6×	0.010	PNPLA3
negative regulation of release of cytochrome c from mitochondria	1	200.6×	0.010	OPA1
embryonic brain development	1	200.6×	0.010	MED12
triglyceride biosynthetic process	1	183.2×	0.010	PNPLA3
post-anal tail morphogenesis	1	183.2×	0.010	MED12
protein complex oligomerization	1	168.5×	0.010	OPA1

Therapeutics

Drugs indicated for this disease

0 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dapagliflozin	Phase 3 (in late-stage trials)
Metformin	Phase 3 (in late-stage trials)
OMEGA-3 FATTY ACIDS	Phase 3 (in late-stage trials)
Pioglitazone	Phase 3 (in late-stage trials)
Rimonabant	Phase 3 (in late-stage trials)
Saroglitazar	Phase 3 (in late-stage trials)
Vitamin E	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cannabidiol, Cholic Acid, Fish Oil, Icomidocholic Acid, Icosapent, Pentoxifylline, Spironolactone.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 2 · Phased (≥1): 3 · Undrugged: 2

Druggability breadth: 3 of 5 evidence-associated genes (60%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
OPA1	MOMELOTINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
OPA1	2	4
MED12	1	2
PRMT7	1	3
PNPLA3	0	0
MT-TL1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
MOMELOTINIB	4	OPA1
ADEMETIONINE	3	PRMT7
TIVANTINIB	3	OPA1
MOLIBRESIB	2	MED12

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PRMT7	100	Binding:98, Functional:2
MED12	6	Binding:6
OPA1	2	Binding:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PRMT7	2.1.1.321	type III protein arginine methyltransferase
OPA1	3.6.5.5	dynamin GTPase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
PRMT7	100

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

3 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
MOMELOTINIB	4	OPA1
TIVANTINIB	3	OPA1
MOLIBRESIB	2	MED12

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	OPA1
B	Phased (≥1) drug, not yet approved	2	MED12, PRMT7
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	PNPLA3, MT-TL1

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PNPLA3	0	—
MT-TL1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 203.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	135
PHASE2	21
PHASE4	16
PHASE1/PHASE2	9
PHASE3	8
PHASE1	8
EARLY_PHASE1	4
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03851627	PHASE4	RECRUITING	Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism
NCT06989723	PHASE4	RECRUITING	Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
NCT00160407	PHASE4	COMPLETED	Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
NCT00207311	PHASE4	COMPLETED	Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
NCT00274495	PHASE4	TERMINATED	Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver
NCT00736385	PHASE4	TERMINATED	Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT00742326	PHASE4	TERMINATED	Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
NCT01720719	PHASE4	UNKNOWN	Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
NCT01761318	PHASE4	COMPLETED	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
NCT02102646	PHASE4	COMPLETED	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
NCT02210715	PHASE4	COMPLETED	Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients
NCT02660047	PHASE4	COMPLETED	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent
NCT02669641	PHASE4	UNKNOWN	Complex Imaging Assessment of Steatosis
NCT03374358	PHASE4	COMPLETED	Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
NCT03646292	PHASE4	COMPLETED	Antidiabetic Drugs for Steatotic Liver Disease
NCT05898841	PHASE4	COMPLETED	Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
NCT00063635	PHASE3	COMPLETED	Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
NCT00244569	PHASE3	COMPLETED	Development of a Breath Test for Monitoring Patients With Liver Disease
NCT00303537	PHASE2/PHASE3	UNKNOWN	Metformin in Non-Alcoholic Fatty Liver Disease
NCT00576667	PHASE3	TERMINATED	An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
NCT00577148	PHASE3	TERMINATED	An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
NCT00681408	PHASE2/PHASE3	COMPLETED	Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
NCT01934777	PHASE3	COMPLETED	Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
NCT01992809	PHASE3	COMPLETED	Omega 3 Supplementation in Fatty Liver
NCT02265276	PHASE3	UNKNOWN	A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
NCT05308160	PHASE3	UNKNOWN	A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease
NCT05979779	PHASE2	ACTIVE_NOT_RECRUITING	Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
NCT05984745	PHASE2	RECRUITING	Effect of CoQ10 on the Outcome of MAFLD Patients
NCT06302049	PHASE1/PHASE2	RECRUITING	Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
NCT06588699	PHASE2	RECRUITING	Digoxin In NASH (CODIN)
NCT06599918	PHASE2	RECRUITING	Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
NCT07238985	PHASE1/PHASE2	RECRUITING	Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
NCT07242222	PHASE1/PHASE2	RECRUITING	Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
NCT00013598	PHASE2	COMPLETED	Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
NCT00068094	PHASE1/PHASE2	TERMINATED	The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics
NCT00152815	PHASE2	TERMINATED	Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
NCT00266019	PHASE2	COMPLETED	Weight Management in Nonalcoholic Steatohepatitis
NCT00323414	PHASE2	COMPLETED	Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
NCT00443079	PHASE2	COMPLETED	A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)
NCT00501592	PHASE2	COMPLETED	Study of INT-747 in Patients With Diabetes and Presumed NAFLD

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VITAMIN E	4	4
CHOLINE	4	2
LIRAGLUTIDE	4	2
ORLISTAT	4	2
PIOGLITAZONE	4	2
RIBAVIRIN	4	2
RIMONABANT	4	2
BISMUTH SUBCITRATE POTASSIUM	4	1
CANNABIDIOL	4	1
CILOSTAZOL	4	1
CYSTEAMINE	4	1
DIGOXIN	4	1
EMPAGLIFLOZIN	4	1
ERDOSTEINE	4	1
METFORMIN	4	1
NIACINAMIDE	4	1
OBETICHOLIC ACID	4	1
OMEGA-3-ACID ETHYL ESTERS	4	1
PEGINTERFERON ALFA-2A	4	1
PEGVISOMANT	4	1
PENTOXIFYLLINE	4	1
RALTEGRAVIR	4	1
TESAMORELIN	4	1
TESTOSTERONE UNDECANOATE	4	1
TRIPTORELIN	4	1
ADEMETIONINE	3	1
BISMUTH SUBCITRATE	3	1
GINGER	3	1
ICOMIDOCHOLIC ACID	3	1
ITOPRIDE	3	1

Cohort genes: MED12, PNPLA3, PRMT7, MT-TL1, OPA1
Drugs: Vitamin E, Choline, Liraglutide, Orlistat, Pioglitazone, Ribavirin, Rimonabant, Bismuth Subcitrate, Cannabidiol, Cilostazol, Cysteamine, Digoxin, Empagliflozin, Erdosteine, Metformin, Niacinamide, Obeticholic Acid, OMEGA-3-ACID ETHYL ESTERS, PEGINTERFERON ALFA-2A, Pegvisomant, Pentoxifylline, Raltegravir, Tesamorelin, Testosterone Undecanoate, Triptorelin, Ademetionine, Bismuth Subcitrate, Ginger, Icomidocholic Acid, Itopride